No altered risk of IBD associated with the overall use of GLP-1 based therapies

In the following MEDtalk, Heidi Søgaard Christensen from PREDICT, Copenhagen, discusses the initial study exploring the impact of GLP-1 based therapies on the likelihood of individuals with type 2-diabetes developing IBD. The investigation was prompted by a prior study that linked the use of DPP4i to a higher risk of inflammatory bowel disease (IBD), although two other studies found no significant changes in risk.